Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Downgrades Hill-Rom Holdings to Neutral, Raises Price Target to $156

Baird analyst Mike Polark downgrades Hill-Rom Holdings (NYSE:HRC) from Outperform to Neutral and raises the price target from $150 to $156.

byvishwanath@benzinga.com

September 3, 2021

1 minute read

Baird analyst Mike Polark downgrades Hill-Rom Holdings (NYSE:HRC) from Outperform to Neutral and raises the price target from $150 to $156.

Autonomous Truck Company Embark Eyes $5.2B SPAC Merger To Go Public: WSJ

By Anusuya Lahiri

Today, 3:18 AM

The self-driving truck startup, Embark Trucks Inc, is planning to go public via the special-purpose acquisition company (SPAC)…

AMZN

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $50

By Benzinga Newsdesk

Today, 3:18 AM

BTIG analyst David Larsen maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $60 to $50.

HCAT

Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical

By Vandana Singh

Today, 3:18 AM

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) acquired the investigational new drug application for an ongoing Phase 2 TATCIST trial evaluating 225Ac-PSMA…

FUSN

NorthEast Community Q4 EPS $0.27 Up From $0.22 YoY

By Benzinga Newsdesk

Today, 3:18 AM

NorthEast Community (NASDAQ:NECB) reported quarterly earnings of $0.27 per share. This is a 22.73 percent increase over earnings of $0.22 per share from the same period last year.

NECB

Baird Downgrades Hill-Rom Holdings to Neutral, Raises Price Target to $156

Related Posts

Autonomous Truck Company Embark Eyes $5.2B SPAC Merger To Go Public: WSJ

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $50

Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical

NorthEast Community Q4 EPS $0.27 Up From $0.22 YoY